1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
2.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2023 (US$ Million)
2.3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-Use, 2023 (US$ Million)
2.4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
3.2. Strategies Adopted by Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
3.3. Key Industry Strategies
4. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Vitamin E and Pioglitazone
5.3.2. Obeticholic Acid (OCA)
5.3.3. Lanifibranor
5.3.4. Semaglutide
5.3.5. Resmetirom
5.3.6. Aramchol
5.3.7. Cenicriviroc
5.3.8. Others

6. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospital Pharmacies
6.3.2. Retail & Specialty Pharmacies
6.3.3. Others


7. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
7.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.1.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.2.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.3.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)

8. UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.1.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.2.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.3.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.4.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.5.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.6.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)

9. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.1.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.2.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.3.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.4.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.5.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.6.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)

10. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
10.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.1.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.2.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.3.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)

11. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
11.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.1.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.2.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.3.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-Use, 2022-2032, USD (Million)

12. Company Profile
12.1. Intercept Pharmaceuticals
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Galmed Pharmaceuticals
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Inventiva Pharma
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. AbbVie Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Galectin Therapeutics Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Madrigal Pharmaceuticals
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. NGM Biopharmaceuticals Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Novo Nordisk A/S
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Bristol Myers Squibb
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Gilead Sciences Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Other Notable Players
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives